Loading…
← CockpitCompetitor Analysis › 688065.SS Cathay Biotech, Inc. Class AOpen in the cockpit ↗

Cathay Biotech, Inc. Class A688065.SSCompetitor analysis, valuation and peers

China · CNY·Materials›Chemicals: Specialty

Chinese biotechnology company using industrial fermentation to make bio-based chemicals, including long-chain diacids and bio-based nylon (PA56).

≈ A Chinese Genomatica/DuPont Tate & Lyle for bio-based materialsMomentum neutral 44
Mkt cap
$3.77B
US dollars, full cap
Free float
46%
of shares outstanding
$/day
$21.0M
20-day average traded
Fwd P/E
34.3×
forward earnings
ROIC−WACC
-5.8 pp
WACC 9.5%
Hurdle
n/a
no reverse DCF
Next earnings
162 days
29 Apr 2027
Close · CNYCN¥35.12
1D-1.8%
1W-10.2%
1M-5.2%
3M-24.6%
6M-23.4%
YTD-29.5%
1Y-27.6%
ATR %3.4%
52w lowhigh45.5% off high

What Cathay Biotech does

Chinese biotechnology company using industrial fermentation to make bio-based chemicals, including long-chain diacids and bio-based nylon (PA56).

Produces its chemicals by fermentation, growing engineered microbes on plant sugars, and sells them as ingredients to makers of nylon, fragrances, coatings and other materials. Long-chain diacids are the established earner, while bio-based nylon is a newer material still being introduced to textile and plastics customers.

In one line: A Chinese Genomatica/DuPont Tate & Lyle for bio-based materials.

Products and services

  • Long-chain dicarboxylic acids
  • Bio-based nylon (PA56, Terryl fiber)
  • Bio-based polyols/other fermentation chemicals

Customers

  • Textile/apparel makers
  • Engineering plastics/chemical companies

Where it sits in the supply chain

  • Materials
  • Specialty chemicals
  • Bio-based/fermentation chemicals

What could go right

  • Sustainable/bio-based material demand growth

What could go wrong

  • High capex/ramp-up execution risk
  • Competition from petrochemical-based incumbents on cost

Moat: narrow (IP / patents, process know-how). Proprietary synthetic-biology/fermentation strains and processes that are difficult to replicate.

Headquarters: Shanghai, China · Employees: 1,761

Named competitors

Cathay Biotech at a glance

Size Cathay Biotech (688065.SS) is a China Materials company (Chemicals: Specialty) with a market value of $3.77B, the 640th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥35.12 on 18 Nov 2026.

Performance Over six months the shares fell 23.4%, against -25.6% for the median peer and -20.0% for the China market (cap-weighted) — 9th highest of 21 in its peer set.

Growth Revenue grew 9.4% over the last twelve months (peer median +10.9%); the operating margin is 17.8% (peer median 12.0%).

Valuation It trades at 34.3× forward earnings against a peer median of 14.9× (5th most expensive of 21).

Capital Return on invested capital runs 5.8 points below its cost of capital (9.5% WACC).

Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026688065.SS 78Peer median 78
Six months, rebased to 100: Cathay Biotech against the median of its 20 peers (local-currency closes).

Cathay Biotech financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥3.59BCN¥3.29BCN¥2.95BCN¥2.11BCN¥2.43B
Revenue growth—+11%+40%-13%—
Gross profitCN¥1.42BCN¥1.06BCN¥849MCN¥554MCN¥783M
EBITDAn/aCN¥800MCN¥676MCN¥440MCN¥650M
Net incomeCN¥637MCN¥561MCN¥489MCN¥367MCN¥553M
Free cash flow-CN¥270M-CN¥326M-CN¥22.4M-CN¥1.00B-CN¥3.39B
Capital expenditureCN¥1.03BCN¥743MCN¥843MCN¥1.57BCN¥4.20B
Total debtCN¥891MCN¥503MCN¥1.90BCN¥1.81BCN¥1.13B

Quarterly statements and history in the cockpit →

Cathay Biotech competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-10%0%+10%4182CBT6002990024303008960024074403000629002340688300603379CLN60030100068360088440881402HWKNHPOL-BDESN688065.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Cathay Biotech is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%+30%20×40×4182CBT6002990024303008960024074403000629002340688300603379CLN60030100068360088440881402HWKNDESN688065.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Cathay Biotech is the large dot.

Cathay Biotech competitors and peer comparison

Head to head with its named competitors (688065.SS vs EVK.DE vs AKE.PA vs 3402.T)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Cathay Biotech 688065.SS$3.77B-23%+9%18%34.3×n/a
Evonik Industries EVK.DE$11.1B+27%+2%10%12.1×-5.6%
Arkema AKE.PA$4.83B-3%-2%5%13.3×12.3%
Toray Industries 3402.T$12.4B+15%+10%6%18.2×5.4%
Ube 4208.T$1.94B+34%+8%5%11.9×n/a

How Cathay Biotech compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Cathay Biotech against its 20 peers (data as of 18 Nov 2026)
Measure688065.SSPeer medianRank in peer set
1-month return-5.2%-2.7%10th lowest of 21
6-month return-23.4%-25.6%9th highest of 21
Distance from 52-week high-45.5%-40.6%7th lowest of 21
Revenue growth (TTM)+9.4%+10.9%10th lowest of 21
Operating margin17.8%12.0%6th highest of 21
Forward P/E34.3×14.9×5th most expensive of 21
ROIC minus cost of capital-5.8 pp+3.6 pplowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Cathay Biotech 688065.SSChina$3.77B-23%+9%18%34.3×n/an/a
Mitsubishi Gas Chemical 4182.TJapan$3.76B-32%+9%9%10.2×n/an/a
Cabot CBTUnited States$3.80B-5%+1%14%11.3×-2.3%+1.9%
Bluestar Adisseo 600299.SSChina$3.70B-34%+15%13%11.3×-9.4%+7.7%
Hangzhou Oxygen Plant 002430.SZChina$3.70B-16%+16%11%19.8×2.2%+8.5%
IMEIK Technology Development 300896.SZChina$3.66B-25%-7%45%22.4×17.5%+28.0%
Do-Fluoride New Materials 002407.SZChina$3.62B-42%+69%7%33.9×17.3%+17.5%
NOF 4403.TJapan$3.60B-10%+22%17%13.6×-7.4%+8.4%
Pangang Group Vanadium & Titanium Resources 000629.SZChina$3.60B-26%+6%4%57.3×26.1%-3.4%
GEM 002340.SZChina$4.12B-35%+2%7%14.6×3.5%+24.4%
Novoray 688300.SSChina$3.40B-39%+23%26%49.8×45.5%+22.6%
Zhejiang Sanmei Chemical Industry 603379.SSChina$4.20B-27%+24%41%12.2×3.8%+16.5%
Clariant CLN.SWSwitzerland$4.20B+35%-7%10%16.3×-3.3%+0.3%
Guangxi Huaxi Nonferrous Metal 600301.SSChina$4.27B-25%+24%32%22.6×9.1%+44.9%
Inner Mongolia Berun Chemical 000683.SZChina$3.28B-27%+11%13%13.8×n/an/a
Ningbo Shanshan 600884.SSChina$3.27B-35%+30%9%12.2×2.8%+21.3%
Air Water 4088.TJapan$4.34B+34%+11%3%11.8×9.4%+6.8%
Far Eastern New Century 1402.TWTaiwan$4.39B+2%+5%7%11.5×4.7%+4.2%
Hawkins HWKNUnited States$3.19B-1%+9%11%34.4×15.9%+12.7%
Hexpol HPOL-B.STSweden$3.10B+19%-1%14%15.2×2.9%+7.6%
Dottikon ES DESN.SWSwitzerland$4.63B-26%+11%27%38.2×13.4%+14.4%

Questions

Who are Cathay Biotech's main competitors?
Named competitors: Evonik Industries (EVK.DE), Arkema (AKE.PA), Toray Industries (3402.T), Ube Corporation (4208.T). The cockpit's measured peer set (industry) also includes Mitsubishi Gas Chemical (4182.T), Cabot (CBT), Bluestar Adisseo (600299.SS), Hangzhou Oxygen Plant (002430.SZ), IMEIK Technology Development (300896.SZ), Do-Fluoride New Materials (002407.SZ).
Is Cathay Biotech expensive compared with its peers?
On forward p/e it trades at 34.3× against a peer median of 14.9×, 5th most expensive of 21 in its peer set.
How has Cathay Biotech stock performed?
Over six months to 18 Nov 2026 the shares returned -23.4% against -25.6% for the median peer; over one year -27.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.